Comparative risk of musculoskeletal adverse reactions among new users of dipeptidyl peptidase-4 inhibitors: A retrospective cohort study

Background: The effects of dipeptidyl peptidase-4 inhibitors (DPP4Is) on joint pain have been controversial. Objective: To assess the comparative musculoskeletal (MSk) risk of DPP4Is vs. non-DPP4Is. Methods: This study used a national claims database from January 2007 to December 2014. Exposure incl...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Taehwan Park, Maureen Bresnahan, Scott K. Griggs, Jiajing Chen, Alex H. Cho, Yolene Gousse, Mark Feinglos
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	DPP4 inhibitors Comparative risk Musculoskeletal adverse reactions Pharmacoepidemiology Pharmacy and materia medica RS1-441
Acceso en línea:	https://doaj.org/article/4b30003fb79b49d5afb77117d8906514
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4b30003fb79b49d5afb77117d8906514
record_format	dspace
spelling	oai:doaj.org-article:4b30003fb79b49d5afb77117d89065142021-11-04T04:44:56ZComparative risk of musculoskeletal adverse reactions among new users of dipeptidyl peptidase-4 inhibitors: A retrospective cohort study2667-276610.1016/j.rcsop.2021.100022https://doaj.org/article/4b30003fb79b49d5afb77117d89065142021-06-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2667276621000226https://doaj.org/toc/2667-2766Background: The effects of dipeptidyl peptidase-4 inhibitors (DPP4Is) on joint pain have been controversial. Objective: To assess the comparative musculoskeletal (MSk) risk of DPP4Is vs. non-DPP4Is. Methods: This study used a national claims database from January 2007 to December 2014. Exposure included the initiation of DPP4Is against the initiation of non-DPP4Is: metformin, sulfonylureas, thiazolidinediones, meglitinides, and glucagonlike peptide-1 receptor agonists (GLP-1 RAs). Insulin was not included in this study. Outcomes were newly diagnosed MSk conditions (arthralgia, arthropathy, and rheumatoid arthritis or other inflammatory polyarthropathies). Individuals exposed to DPP4Is were matched to those exposed to non-DPP4Is using a propensity score (PS). Balance between the DPP4I's group and the non-DPP4I's group was assessed using standardized differences for both continuous and categorical variables. Cox regressions were used to estimate hazard ratios (HRs) for MSk conditions. Results: Among PS-matched cohorts, incidence rates (IRs) for MSk conditions did not differ between DPP4I initiators and non-DPP4I initiators (HR = 1.01, 95% CI: 0.97–1.05). After stratifying non-DPP4Is by drug class, the results still showed that DPP4I initiators had similar MSk risk when compared to initiators of metformin, sulfonylureas, meglitinides, and GLP-1 RAs. However, thiazolidinedione initiators had higher risk of MSk conditions than DPP4I initiators (HR = 1.05, 95% CI: 1.00–1.10). Conclusions: This head-to-head comparison study estimated comparative MSk risks among different antidiabetic drugs. The risk of MSk conditions among DPP4I initiators were not significantly higher than non-DPP4I initiators.Taehwan ParkMaureen BresnahanScott K. GriggsJiajing ChenAlex H. ChoYolene GousseMark FeinglosElsevierarticleDPP4 inhibitorsComparative riskMusculoskeletal adverse reactionsPharmacoepidemiologyPharmacy and materia medicaRS1-441ENExploratory Research in Clinical and Social Pharmacy, Vol 2, Iss , Pp 100022- (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	DPP4 inhibitors Comparative risk Musculoskeletal adverse reactions Pharmacoepidemiology Pharmacy and materia medica RS1-441
spellingShingle	DPP4 inhibitors Comparative risk Musculoskeletal adverse reactions Pharmacoepidemiology Pharmacy and materia medica RS1-441 Taehwan Park Maureen Bresnahan Scott K. Griggs Jiajing Chen Alex H. Cho Yolene Gousse Mark Feinglos Comparative risk of musculoskeletal adverse reactions among new users of dipeptidyl peptidase-4 inhibitors: A retrospective cohort study
description	Background: The effects of dipeptidyl peptidase-4 inhibitors (DPP4Is) on joint pain have been controversial. Objective: To assess the comparative musculoskeletal (MSk) risk of DPP4Is vs. non-DPP4Is. Methods: This study used a national claims database from January 2007 to December 2014. Exposure included the initiation of DPP4Is against the initiation of non-DPP4Is: metformin, sulfonylureas, thiazolidinediones, meglitinides, and glucagonlike peptide-1 receptor agonists (GLP-1 RAs). Insulin was not included in this study. Outcomes were newly diagnosed MSk conditions (arthralgia, arthropathy, and rheumatoid arthritis or other inflammatory polyarthropathies). Individuals exposed to DPP4Is were matched to those exposed to non-DPP4Is using a propensity score (PS). Balance between the DPP4I's group and the non-DPP4I's group was assessed using standardized differences for both continuous and categorical variables. Cox regressions were used to estimate hazard ratios (HRs) for MSk conditions. Results: Among PS-matched cohorts, incidence rates (IRs) for MSk conditions did not differ between DPP4I initiators and non-DPP4I initiators (HR = 1.01, 95% CI: 0.97–1.05). After stratifying non-DPP4Is by drug class, the results still showed that DPP4I initiators had similar MSk risk when compared to initiators of metformin, sulfonylureas, meglitinides, and GLP-1 RAs. However, thiazolidinedione initiators had higher risk of MSk conditions than DPP4I initiators (HR = 1.05, 95% CI: 1.00–1.10). Conclusions: This head-to-head comparison study estimated comparative MSk risks among different antidiabetic drugs. The risk of MSk conditions among DPP4I initiators were not significantly higher than non-DPP4I initiators.
format	article
author	Taehwan Park Maureen Bresnahan Scott K. Griggs Jiajing Chen Alex H. Cho Yolene Gousse Mark Feinglos
author_facet	Taehwan Park Maureen Bresnahan Scott K. Griggs Jiajing Chen Alex H. Cho Yolene Gousse Mark Feinglos
author_sort	Taehwan Park
title	Comparative risk of musculoskeletal adverse reactions among new users of dipeptidyl peptidase-4 inhibitors: A retrospective cohort study
title_short	Comparative risk of musculoskeletal adverse reactions among new users of dipeptidyl peptidase-4 inhibitors: A retrospective cohort study
title_full	Comparative risk of musculoskeletal adverse reactions among new users of dipeptidyl peptidase-4 inhibitors: A retrospective cohort study
title_fullStr	Comparative risk of musculoskeletal adverse reactions among new users of dipeptidyl peptidase-4 inhibitors: A retrospective cohort study
title_full_unstemmed	Comparative risk of musculoskeletal adverse reactions among new users of dipeptidyl peptidase-4 inhibitors: A retrospective cohort study
title_sort	comparative risk of musculoskeletal adverse reactions among new users of dipeptidyl peptidase-4 inhibitors: a retrospective cohort study
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/4b30003fb79b49d5afb77117d8906514
work_keys_str_mv	AT taehwanpark comparativeriskofmusculoskeletaladversereactionsamongnewusersofdipeptidylpeptidase4inhibitorsaretrospectivecohortstudy AT maureenbresnahan comparativeriskofmusculoskeletaladversereactionsamongnewusersofdipeptidylpeptidase4inhibitorsaretrospectivecohortstudy AT scottkgriggs comparativeriskofmusculoskeletaladversereactionsamongnewusersofdipeptidylpeptidase4inhibitorsaretrospectivecohortstudy AT jiajingchen comparativeriskofmusculoskeletaladversereactionsamongnewusersofdipeptidylpeptidase4inhibitorsaretrospectivecohortstudy AT alexhcho comparativeriskofmusculoskeletaladversereactionsamongnewusersofdipeptidylpeptidase4inhibitorsaretrospectivecohortstudy AT yolenegousse comparativeriskofmusculoskeletaladversereactionsamongnewusersofdipeptidylpeptidase4inhibitorsaretrospectivecohortstudy AT markfeinglos comparativeriskofmusculoskeletaladversereactionsamongnewusersofdipeptidylpeptidase4inhibitorsaretrospectivecohortstudy
_version_	1718445206885367808

Comparative risk of musculoskeletal adverse reactions among new users of dipeptidyl peptidase-4 inhibitors: A retrospective cohort study

Ejemplares similares